louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06641752: Evaluation of CO Intoxication Rate, by CAPillary HbCO
Official title: Evaluation of the Accuracy of Capillary Versus Venous CO Measurement in Subjects With Suspected Carbon Monoxide Poisoning: a Prospective, Multicenter, Diagnostic, Controlled Study.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Carbon Monoxide Intoxication
Keywords: Intoxication
Carbon monoxyde
Carboxyhemoglobin
COHb
Carboxyhemoglobin capillary
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
Collaborators: name: University Hospital, Angers
First posted: 2024-10-15
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population will consist of patients admitted to adult emergency departments with suspected carbon monoxide intoxication.

Brief summary: The main goal of COCAP is to compare COHb (carboxyhemoglobin) levels measured from venous or arterial samples with those measured from capillary samples in patients suspected of Carbon Monoxide intoxication.Patient participation in the study will be limited to capillary sampling (approx. 5-15 minutes).


Eligibility criteria: Inclusion Criteria:

* Adult patient admitted to emergency department
* Presenting one or more clinical signs (asthenia, headache, nausea, vomiting, loss of consciousness, etc.) and a history compatible with CO intoxication (collective symptoms, notion of smoke, activation of a detector, etc.).

Exclusion Criteria:

* Minors
* Patients under protective supervision (safeguard of justice, curatorship, guardianship)
* Incarcerated patients
* Pregnant or breast-feeding women
* Patients refusing to take part in the study

Primary outcomes:
measure: Determine the accuracy of capillary HbCO measurement (compared with venous or arterial HbCO) in patients with suspected CO poisoning.
timeFrame: 15 minutes
Secondary outcomes:
measure: Determine the diagnostic performance of capillary measurement
timeFrame: 15 minutes
measure: Assess the technical difficulties of different blood sampling processes.
timeFrame: 15 minutes
measure: Analyse the technical difficulties associated with the analysis of the two samples.
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
state: Loire-Atlantique
Study officials:
References:
Clinical trial NCT02312752: Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)
Official title: Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Healthy
Keywords: Intra-epidermal stimulation in healthy control subjects
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2014-12-09
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of the study is to determine whether a particular type of nerve fibers, A-delta fibers, can be tested in an Electromyography (EMG) lab on a routine basis. Normal, healthy volunteers will be enrolled in this study.

Detailed description: The epidermis is the outermost layer of the skin that includes skin cells and small nerve fibers called A-delta fibers. A-delta fibers send signals to the brain about pin-prick type of pain and temperature. The investigators want to study whether the investigators can stimulate A-delta fibers and document this by recording electrical potentials from the nerves in subjects' limbs.

Study Procedures:

A small piece of plastic will be applied to your foot and your hand. A tiny sharp tip protrudes from this piece of plastic. You will be barely able to feel this sharp tip when touching the piece of plastic. This is the electrode for intra-epidermal stimulation.

With stimulation, you will feel a pin-prick type of sensation. The stimulus will be adjusted so that you barely feel the pin-prick type of sensation. The investigators will record responses of stimulation from nerves in your skin.

Eligibility criteria: Inclusion Criteria:

* Individuals aged 21 through 60 years with no history or clinical signs of neuropathy.

Exclusion Criteria:

1. History of peripheral nerve disease or disease of somatosensory pathways.
2. Abnormalities on neurologic examination.
3. Prior or current exposure to known neurotoxins, such as excessive alcohol use or chemotherapy.
4. Neurologic or psychiatric conditions that would prevent the subject from being able to cooperate with testing.

Primary outcomes:
measure: Feasibility to selectively stimulate and record from A-delta nerve fibers using the intra-epidermal stimulation electrode as measured by electromyography (EMG)
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: David Walk, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00891852: Non-Invasive Determination of Fetal Chromosome Abnormalities
Official title: Non-Invasive Determination of Fetal Chromosome Abnormalities
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Down Syndrome (Trisomy 21)
Edward's Syndrome (Trisomy 18)
Patau Syndrome (Trisomy 13)
Klinefelter Syndrome (47, XXY)
and Other Chromosome
Abnormalities.
Lead sponsor: Lenetix Medical Screening Laboratory
Sponsor class: INDUSTRY
First posted: 2009-05-01
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators anticipate enrolling 1000 subjects who are presenting for prenatal diagnosis by CVS or genetic amniocentesis for increased risk for fetal aneuploidy.

Brief summary: The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and CVS procedures.


Eligibility criteria: Inclusion Criteria:

* This study is only applicable to women who are between 8 and 30 weeks' gestation and who have been determined increased risk for fetal aneuploidy. In the interest of expediting and simplifying this study, the investigators want only women who have already decided to undergo second-trimester amniocentesis or CVS.

Exclusion Criteria:

* The only exclusion criteria are those mentioned.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rockville
country: United States
facility: Maryland Perinatal Associates
state: Maryland
city: Moristown
country: United States
facility: Atlantic Maternal Fetal Medicine
state: New Jersey
city: Mineola
country: United States
facility: Winthrop University Hospital
state: New York
city: New Hyde Park
country: United States
facility: Elite Women's Health
state: New York
city: New York
country: United States
facility: Columbia University, NewYork-Presbyterian Hospital
state: New York
city: New York
country: United States
facility: New York Perinatal Associates
state: New York
city: Burlington
country: United States
facility: UVM
state: Vermont
Study officials:
affiliation: Lenetix, Inc.
name: Stephen A Brown, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00296452: Effect of a Nutritional Supplement on H&N Cancer Patients
Official title: The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Head and Neck Cancer
Keywords: cancer
nutrition
Lead sponsor: Edward Hines Jr. VA Hospital
Sponsor class: FED
First posted: 2006-02-27
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: To determine if using a nutritionally enhanced supplement will improve mucositis in head and neck cancer patients

Detailed description: H\&N cancer patients will be randomized to receive either a nutritionally enhanced product or standard treatment. The patients in both groups will receive nutritional counseling weekly by the RD. Anthropometric measures, available lab values, mucositis grade, and quality of life measures will be compared between groups.

Eligibility criteria: Inclusion Criteria:

* Head and neck cancer 1st.2nd wk Rx read \&wrte eng

Exclusion Criteria:

* receiving hospice impaired cognition

Primary outcomes:
measure: severity of mucositis
Secondary outcomes:
measure: weight loss, quality of life
Other outcomes:
Locations:
city: Hines
country: United States
facility: Edward Hines, Jr. VA Hospital
state: Illinois
city: Hines
country: United States
facility: Hines VA Hospital
state: Illinois
Study officials:
affiliation: Hines VA Hosptial
name: Sharon Foley, MS
role: PRINCIPAL_INVESTIGATOR
affiliation: Hines VA Hospital
name: carol bier-laning, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04605952: Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive
Official title: Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Lead sponsor: Tata Main Hospital
Sponsor class: OTHER
First posted: 2020-10-28
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Asymptomatic workforce

Brief summary: As a serosurveillance measure asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies. Of the tested employees who were positive for COVID-19 IgG antibodies the study aimed to find the percentage of cases who retained their COVID-19 IgG antibodies 45-65 days after initially testing positive.

Detailed description: As a serosurveillance measure, 3296 asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies specific for the spike subunit antigen by the ErbaLisa COVID-19, Erba Corporate Services (United Kingdom) between 28th June and 15th July 2020.

The cases who tested positive for COVID-19 IgG antibodies were repeat tested for the presence of COVID-19 IgG at 45-65 days after initially testing positive. This was done with the aim of finding out the percentage of cases retaining their IgG antibodies at 45-65 days of initially testing positive.

Eligibility criteria: Inclusion Criteria:

SARS-CoV-2 IgG antibody positive between 28th June and 15th July 2020

Exclusion Criteria:

SARS-CoV-2 IgG antibody negative between 28th June and 15th July 2020

Primary outcomes:
measure: Percentage of cases retaining SARS-CoV-2 IgG antibodies at 45-65 days
timeFrame: 45-65 days
Secondary outcomes:
Other outcomes:
Locations:
city: Jamshedpur
country: India
facility: Dr.Deb Sanjay Nag
state: Jharkhand
Study officials:
affiliation: Tata Main Hospital
name: DR.DEB S NAG, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01615952: Patient Positioning on Supraclavicular Nerve Block
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Nerve Block
Keywords: Supraclavicular Block
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2012-06-11
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients 18 y/o to 65 y/o, who are scheduled to receive a ultrasound-guided supraclavicular nerve block as part of their postoperative pain management.

Brief summary: Blockade of the brachial plexus using a supraclavicular approach provides excellent anesthesia for upper extremity surgery. The most serious complication specific to this block is pneumothorax. Subsequent modifications of this block including the use of ultrasound have lowered the risk from 6% to \<1%. Case reports remain and authors have described certain factors and strategies to reduce this risk. Most texts and journals describe the patient in a supine or semi-sitting position during the block. At the investigators institution the investigators perform the block in a semi-sitting position to facilitate needle tip visibility with ultrasound. The investigators plan to obtain ultrasound anatomic measurements in three different positions (supine, semi-sitting, sitting) using patients consented for supraclavicular nerve blocks.


Eligibility criteria: Inclusion Criteria:

* all patients, 18 y/o to 65 y/o, who are scheduled to receive an ultrasound- guided supraclavicular nerve block

Exclusion Criteria:

* patient refusal to be included in the study,
* the presence of language barrier that inhibits proper communication with the patient, contraindications to regional anesthesia (local infection, severe pulmonary disease, or preexisting neuropathy)
* history of allergy to amide local anesthetics or narcotics
* the presence of a progressive neurological deficit
* history of hepatorenal insufficiency
* the presence of a coagulopathy or infection
* pregnancy
* a history of psychiatric disorder
* inability to follow study protocol

Primary outcomes:
measure: patient positioning
timeFrame: Postoperative Day One
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University Feingberg School of Medicine
state: Illinois
Study officials:
References:
Clinical trial NCT03322852: Effect of Clomiphene Citrate on Uterine Blood Fow in Women With Unexplained Delayed Conception
Official title: Effect of Clomiphene Citrate on Uterine Hemodynamics in Women With Unexplained Infertility
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-10-26
Enrollment: 50
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had unexplained infertility

Brief summary: In a prospective observational study at a university teaching hospital, blood flow indices and serum hormone levels were compared between spontaneous and stimulated cycles in the same group of 50 patients with unexplained delayed conception.

Detailed description: In a prospective observational study at a university teaching hospital, the mid-luteal (peri-implantation) endometrial thickness and volume, uterine artery pulsatility index (PI) and resistance index (RI), endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were compared between spontaneous and clomiphene citrate stimulated cycles in the same group of 50 patients with unexplained infertility.

Eligibility criteria: Inclusion Criteria:

* Unexplained infertility
* Body mass index less than 30
* Regular menstruation
* Normal pelvic examination and ultrasonography

Exclusion Criteria:

* History of pelvic operations including cesarean section
* History of pelvic inflammatory disease
* Endometriosis
* Pelvic pathology including uterine fibroids
* General disease or medication that could potentially affect pelvic blood flow
* Smoking

Primary outcomes:
measure: Flow index of the endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
Secondary outcomes:
measure: Vascularization index of the endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
measure: Vascularization flow index of the endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
measure: Vascularization flow index of the sub-endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
measure: Flow index of the sub-endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
measure: Vascularization index of the sub-endometrial region
timeFrame: Day 22 to 24 of the menstrual cycle
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Department of Obstetrics and Gynecology, Kasr Al-Ainy hospital, Cairo University
state: Greater Cairo
Study officials:
affiliation: Cairo University
name: Eman Omran, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04063436: Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
Official title: Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: Fisher and Paykel Healthcare
Sponsor class: INDUSTRY
First posted: 2019-08-21
Enrollment: 0
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: After the baseline period, all participants will be trialed on the same new nasal pillows mask.
Primary purpose: TREATMENT

Brief summary: This clinical trial is designed to evaluate the performance, comfort, and usability of a new nasal pillows mask for the treatment of obstructive sleep apnea (OSA) in a home environment.


Eligibility criteria: Inclusion Criteria:

* Are ≥22 years of age
* Weigh ≥66 lbs
* Have been formally diagnosed with OSA by a physician
* Have an AHI ≥5 on a diagnostic night
* Have been prescribed PAP therapy to treat OSA by a physician
* Are an existing nasal pillows mask user
* Have been using a nasal pillows mask for ≥3 months prior to enrolment into the study
* Are compliant with PAP therapy for ≥4 hours per night for 70% of nights
* Are fluent in spoken and written English
* Possess the capacity to provide informed consent

Exclusion Criteria:

* Are intolerant to PAP therapy
* Possess, or suffer from, anatomical or physiological conditions which make PAP therapy inappropriate
* Are currently diagnosed with respiratory disease or CO2 retention
* Are pregnant or think they may be pregnant
* Have an IPAP pressure of \>25 cmH2O
* Persons who use a PAP therapy machine for the delivery of medicines, except O2
* Use a PAP therapy machine that does not possess data recording capabilities to capture AHI and leak information that is accessible to OSMI

Primary outcomes:
measure: Performance of new nasal pillows mask
timeFrame: 14±5 days
Secondary outcomes:
measure: Comfort of new nasal pillows mask
timeFrame: 14±5 days
measure: Usability of new nasal pillows mask
timeFrame: 14±5 days
Other outcomes:
Locations:
city: Dublin
country: United States
facility: Ohio Sleep Medicine Institute
state: Ohio
Study officials:
References:
Clinical trial NCT05134636: Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
Official title: Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Solid Tumor
Patient Empowerment
Telemedicine
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2021-11-26
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The primary objective is to test whether a text-based e-triage can safely minimize the time associated with routine cancer care by identifying patients who can proceed directly to their immunotherapy infusion without a preceding in-person office assessment.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* Initiating singe agent PDL-1/PD-1 targeted immune checkpoint blockade for any solid malignancy at Penn's Abramson Cancer Center
* Access to a mobile phone with texting capabilities
* ECOG performance status less than or equal to 2

Exclusion Criteria:

* Non-English speaking
* Unable to perform informed consent

Primary outcomes:
measure: Healthcare Time
timeFrame: 3 months
Secondary outcomes:
measure: Total Wait Time
timeFrame: 3 months
measure: Total Number of Hospitalization/Emergency Department Encounters
timeFrame: 3 months
measure: Patient Satisfaction as Assessed by the Patient Satisfaction Questionnaire Short Form (PSQ-18)
timeFrame: 3 months
measure: Health Related Quality of Life as Assessed by the Functional Assessment of Cancer Therapy-General (FACT-G)
timeFrame: 3 months
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Perelman Center for Advanced Care
state: Pennsylvania
Study officials:
affiliation: Fellow
name: Erin Bange, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty
name: Ronac Mamtani, MD, MSCE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00008736: Electrogastrography (EGC) in Premature Infants With Feeding Intolerance
Official title: Electrogastrography (EGC) in Premature Infants With Feeding Intolerance: The Effect of Metoclopramide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infant, Newborn, Diseases
Keywords: Feeding intolerance
Infant, premature
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: Children's Hospital of Philadelphia
First posted: 2001-01-18
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: Serial EGC measurements in premature infants attempting to correlate EGC measurements with signs of feeding intolerance and response to metoclopramide therapy.


Eligibility criteria: Inclusion:

Premature infants. Absence of 1) infection, 2) congenital anomalies, 3) growth retardation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
References: